BioPharma Credit Past Earnings Performance
Past criteria checks 2/6
BioPharma Credit has been growing earnings at an average annual rate of 7.7%, while the Capital Markets industry saw earnings growing at 8.6% annually. Revenues have been growing at an average rate of 6.9% per year. BioPharma Credit's return on equity is 8.9%, and it has net margins of 80.2%.
Key information
7.7%
Earnings growth rate
7.9%
EPS growth rate
| Capital Markets Industry Growth | 16.3% |
| Revenue growth rate | 6.9% |
| Return on equity | 8.9% |
| Net Margin | 80.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioPharma Credit makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 136 | 109 | 27 | 0 |
| 31 Mar 24 | 136 | 109 | 27 | 0 |
| 31 Dec 23 | 136 | 108 | 27 | 0 |
| 30 Sep 23 | 178 | 147 | 31 | 0 |
| 30 Jun 23 | 221 | 185 | 36 | 0 |
| 31 Mar 23 | 219 | 184 | 36 | 0 |
| 31 Dec 22 | 218 | 182 | 36 | 0 |
| 30 Sep 22 | 173 | 146 | 27 | 0 |
| 30 Jun 22 | 128 | 109 | 19 | 0 |
| 31 Mar 22 | 116 | 97 | 19 | 0 |
| 31 Dec 21 | 104 | 85 | 19 | 0 |
| 30 Sep 21 | 109 | 89 | 20 | 0 |
| 30 Jun 21 | 114 | 93 | 21 | 0 |
| 31 Mar 21 | 112 | 91 | 21 | 0 |
| 31 Dec 20 | 110 | 89 | 21 | 0 |
| 30 Sep 20 | 111 | 86 | 25 | 0 |
| 30 Jun 20 | 112 | 83 | 30 | 0 |
| 31 Mar 20 | 132 | 103 | 29 | 0 |
| 31 Dec 19 | 151 | 122 | 29 | 0 |
| 30 Sep 19 | 146 | 119 | 26 | 0 |
| 30 Jun 19 | 142 | 115 | 24 | 0 |
| 31 Mar 19 | 120 | 93 | 23 | 0 |
| 31 Dec 18 | 97 | 70 | 23 | 0 |
| 31 Dec 17 | 34 | 27 | 7 | 0 |
Quality Earnings: BPCP has high quality earnings.
Growing Profit Margin: BPCP's current net profit margins (80.2%) are lower than last year (83.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BPCP's earnings have grown by 7.7% per year over the past 5 years.
Accelerating Growth: BPCP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BPCP had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Capital Markets industry average (11.9%).
Return on Equity
High ROE: BPCP's Return on Equity (8.9%) is considered low.